RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Boston Scientific (BSX – Research Report) on September 27 and set a price target of $50.00. The company’s shares closed yesterday at $39.13.
According to TipRanks, Singh Chadha is an analyst with an average return of -14.9% and a 12.00% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Boston Scientific, Abbott Labs, and Edwards Lifesciences.
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $47.86, which is a 22.31% upside from current levels. In a report released on September 19, BTIG also reiterated a Buy rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $47.50 and a one-year low of $34.98. Currently, Boston Scientific has an average volume of 6.62M.
Based on the recent corporate insider activity of 152 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corporation engages in the manufacturing of medical devices and products that are used in various interventional medical specialties worldwide. The company provides implantable devices including heart monitors, technologies for treating coronary artery disease and other cardiovascular disorders, and devices for diagnosing and treating gastrointestinal and pulmonary problems.
